

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-54. (Canceled)

55. (Withdrawn) A method for treating a c-kit-mediated disorder in a mammal, comprising administering a compound of Claim 1 to a mammal suffering from such a disorder.

56. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: neoplastic diseases, mastocytosis, canine mastocytoma, human gastrointestinal stromal tumor ("GIST"), small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, colorectal carcinomas, gastric carcinomas, gastrointestinal stromal tumors, testicular cancers, glioblastomas, and astrocytomas.

57. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: allergic diseases such as asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis and insect bite skin inflammation and blood sucking parasitic infestation.

58. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: inflammatory diseases, arthritic conditions, rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, and gouty arthritis.


59. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: autoimmune diseases, multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid

arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, and proliferative glomerulonephritis.

60. (Withdrawn) A method according to claim 55 wherein said c-kit-mediated disorder is selected from the group consisting of: graft-versus-host disease and graft rejection.


61. (Canceled)

62. (Currently Amended) A compound according to ~~claim 1~~ of the following formula:



wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**; a cycloalkyl, an aryl or heteroaryl group optionally substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**.


63. (Currently Amended) A compound according to ~~claim 1~~ of the following formula:



wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one ~~heteroatom~~ **substituent selected from the group consisting of a halogen** ~~or a nitrogen atom,~~ **and a pendant basic nitrogen functionality, or** a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from ~~nitrogen,~~ I, Cl, Br, and F, **and a pendant basic nitrogen functionality**; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from ~~nitrogen,~~ I, Cl, Br, and F, **and a pendant basic nitrogen functionality**; or

a -SO₂-R'' group wherein R'' is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom,~~ **and a pendant basic nitrogen functionality**; or a ~~-CO-R or a -CO-NRR'~~ **a -CO-R' or -CO-NR'R''** group, wherein ~~R and R'~~ **R' and R''** are independently chosen from H, an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom,~~ **and a pendant basic nitrogen functionality**.

64. (Currently Amended) A compound according to ~~claim 1~~ of the following formula:




wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**; a cycloalkyl, aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**; or an alkyl, cycloalkyl, aryl or heteroaryl group substituted by a alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**; or

a -SO₂-R'' group wherein R'' is an alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**;

or a ~~CO-R or a CO-NRR'~~ **a -CO-R' or a -CO-NR'R''** group, wherein R and ~~R'~~ **R' and R''** are independently chosen from H or an aryl heteroaryl, alkyl and cycloalkyl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**.


65. (Canceled)

66. (Currently Amended) A compound according to ~~claim 1~~ of the following formula:



wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~ **and a pendant basic nitrogen functionality**; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~ **and a pendant basic nitrogen functionality**; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~ **and bearing a pendant basic nitrogen functionality**.

67. (Currently Amended) A compound according to ~~claim 1~~ of formula II:



FORMULA II

wherein X is R or NRR' and wherein R and R' are independently chosen from H, an aryl, an heteroaryl, an alkyl and a cycloalkyl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom~~, **and a pendant basic nitrogen functionality**; or an aryl, an heteroaryl, an alkyl and a

cycloalkyl group substituted with an aryl, an heteroaryl, an alkyl and a cycloalkyl group optionally substituted with at least one ~~heteroatom~~ **substituent** selected from the group consisting of a halogen ~~or a nitrogen atom,~~ **and a pendant basic nitrogen functionality,**

R^2 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R^3 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R^4 is halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R^5 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R^6 is one of the following:

(i) an aryl group ~~or a substituted variant thereof bearing any combination, at any one ring position, of~~ **optionally substituted by** one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, ~~and~~ alkoxy, **NO₂ or CN;**

(ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear ~~any combination of~~ one or more substituents;


(iii) a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl, which may additionally bear ~~any combination of~~ one or more substituents.

68. (Currently amended) A compound according to claim 67 selected from the group consisting of:

- (i) ~~1-(4-Methoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 009);~~
- (ii) 1-(4-Bromo-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 010);
- (iii) ~~1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea (example 011);~~

- (iv) 1-(4-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 012);
- ~~(v) 1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(3,4,5-trimethoxy-phenyl)-urea (example 013);~~
- ~~(vi) 4-{3-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-ureido}-benzoic acid ethyl ester (example 014);~~
- (vii) 1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-thiophen-2-yl-urea (example 015);
- ~~(viii) 1-Cyclohexyl-1-(N-Cyclohexyl-formamide)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 016);~~
- ~~(ix) 1-(2,4-Dimethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 017);~~
- ~~(x) 1-(2-Iodo-phenyl)-1-(N-(2-Iodo-phenyl)-formamide)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 018);~~
- (xi) 1-(3,5-Dimethyl-isoxazol-4-yl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 019);
- (xii) 1-(2-Iodo-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 020);
- ~~(xiii) 1-(4-Difluoromethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 021); and~~
- (xiv) 1-(4-Dimethylamino-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 022).

69. (Currently Amended) A compound according to claim 67, wherein X is a ~~substituted-alkyl, aryl or heteroaryl group bearing a nitrogen group represented by~~ **selected from** the structures (a)-(f) shown below:



wherein the wavy line corresponds to the point of attachment to core structure of formula II.

70. (Currently amended) A compound according to claim 67 69, wherein X is group (d) and R^6 is a 3-pyridyl group.

71. (Currently amended) A compound according to claim 67 69, wherein X is group (d) and R^4 is a methyl group.

72. (Currently amended) A compound according to claim 67 69, wherein X is group (d) and R^2 and/or R^3 and/or R^5 is H.

73-77. (Canceled).

78. (Currently amended) The compound of Claim 1 67 which is: 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-4-yl-thiazol-2-ylamino)-phenyl]-benzamide **(example 080)**.


79. (Currently amended) The compound of Claim 1 67 which is: N-{3-[4-(4-cyano-phenyl)-thiazol-2-ylamino]}-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide **(example 081)**.

80. (Currently amended) The compound of claim 1 67 which is: 4-(4-methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide **(example 060)**.

81. (Currently amended) The compound of claim 4 **67** which is: 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide **(example 066)**.

82. (New) A composition comprising a compound of claim 81 and a pharmaceutically acceptable carrier.

83. (New) A compound of formula I:



FORMULA I

wherein R¹ is:

-C(O)R, -C(O)OR, or -CO-NRR', wherein R and R' are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, and cycloalkyl, each optionally substituted with at least one substituent selected from the group consisting of halogen or a pendant basic nitrogen functionality;

R² is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R³ is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁴ is halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁵ is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;

R⁶ is one of the following:

- (i) an aryl group such as phenyl optionally substituted by one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, alkoxy, NO₂ or CN;
- (ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear one or more substituents;
- (iii) a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl, which may additionally bear one or more substituents;

and R⁷ is one of the following:

- (i) an aryl group such as phenyl optionally substituted by one or more substituents;
- (ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear one or more substituents;
- (iii) a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear one or more substituents;
- (iv) H, a halogen selected from I, F, Cl or Br; NH₂, NO₂ and SO₂-R'', wherein R'' is a linear or branched alkyl group optionally substituted with at least one substituent selected from the group consisting of halogen or a pendant basic nitrogen functionality.

84. (New) A composition comprising a compound of claim 83 in a pharmaceutically acceptable carrier.

85. (New) A compound according to claim 83, wherein R¹ is -C(O)R, wherein R is independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, and cycloalkyl, each optionally substituted with at least one substituent selected from the group consisting of halogen or a pendant basic nitrogen functionality.

86. (New) A compound according to claim 85 selected from the group consisting of:

4-(4-Methyl-piperazin-1-ylmethyl)-N-[3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 003);

N-[4-Methyl-3-(4-phenyl-thiazol-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 004);

N-[3-([2,4']Bithiazolyl-2'-ylamino)-4-methyl-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; (example 005);

4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyrazin-2-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 006);

N-[4-Chloro-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 027);

3-Bromo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 028);

3-Iodo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 029);

4-Amino-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 031);

2-Iodo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 032);

4-Iodo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 033);

3-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 045);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-pyridin-4-yl-benzamide (example 046);

4-Dimethylamino-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 047);

4-Aminomethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide(example 057);

4-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide (example 060);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-isonicotinamide (example 063);

2,6-Dichloro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-isonicotinamide (example 064);

3,5-Dibromo-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 067);

4-Diethylaminomethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 068);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-morpholin-4-ylmethyl-benzamide (example 069);

4-Dipropylaminomethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 070);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-piperidin-1-ylmethyl-benzamide (example 071);

4-[(Diisopropylamino)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide(example 072);

3-Fluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 074);

2,3,5,6-Tetrafluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 076);

N-{3-[4-(4-Fluoro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 077);

3-Bromo-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 078);

3-Chloro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide ([example 079](#));

4-[1-(4-Methyl-piperazin-1-yl)-ethyl]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylmethyl)-phenyl]-benzamide ([example 082](#));

N-{4-Methyl-3-[4-(5-methyl-pyridin-3-yl)-thiazol-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide ([example 084](#));

3-Iodo-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide ([example 085](#));

3,5-Dibromo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-[(3-morpholin-4-yl-propylamino)-methyl]-benzamide ([example 087](#));

3-Dimethylamino-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide ([example 088](#));

3-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide ([example 089](#));

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-morpholin-4-yl-benzamide ([example 090](#));

Cyclohexanecarboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide ([example 092](#));

5-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-pentanoic acid ethyl ester ([example 093](#));

1-Methyl-cyclohexanecarboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide ([example 0094](#));

4-tert-Butyl-cyclohexanecarboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide ([example 0095](#));

(N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-morpholin-4-yl-butylamide ([example 096](#));

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-pyrrolidin-1-ylmethyl-benzamide ([example 099](#));

4-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide ([example 104](#));

3,5-Dibromo-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-piperidin-1-ylmethyl-benzamide (example 107);

N-{3-[4-(4-Chloro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 108);

N-{3-[4-(4-Methoxy-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 110);

N-{3-[4-(3-Fluoro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 111);

N-{3-[4-(3-Methoxy-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide(example 113);

4-(4-Methyl-piperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-trifluoromethyl-phenyl)-thiazol-2-ylamino]-phenyl}-benzamide (example 116);

N-{4-Methyl-3-[4-(3-nitro-phenyl)-thiazol-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 117);

N-{3-[4-(2-Fluoro-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 118);

4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-2-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 122);

N-{3-[4-(2,5-Dimethyl-phenyl)-thiazol-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (example 124);

87. (New) A pharmaceutical composition comprising a compound according to claim 85 and a pharmaceutically acceptable carrier.

88. (New) A compound according to claim 83, wherein R¹ is

-CO-NRR', wherein R and R' are independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, and cycloalkyl, each optionally substituted with at least one substituent selected from the group consisting of halogen or a pendant basic nitrogen functionality.

89. (New) A compound according to claim 88 selected from the group consisting of:

1-(2-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 023);

1-(2-Chloro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 024); and

1-(3-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 025);

90. (New) A pharmaceutical composition comprising a compound according to claim 88 and a pharmaceutically acceptable carrier.

91. (New) A compound according to claim 83, wherein R¹ is

-C(O)OR, wherein R is selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, and cycloalkyl, each optionally substituted with at least one substituent selected from the group consisting of halogen or a pendant basic nitrogen functionality.


92 (new) A compound according to claim 91 selected from the group consisting of:

[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester (example 097), and

[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-carbamic acid tert-butyl ester (example 098).

93. (New) A pharmaceutical composition comprising a compound according to claim 92 and a pharmaceutically acceptable carrier.

94. (New) A compound according to the following formula:



wherein R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom, or bearing at least one nitrogen group;

a cycloalkyl, aryl or heteroaryl group optionally substituted with at least one substituent selected from the group consisting of a halogen and a pendant basic nitrogen functionality; or an alkyl, cycloalkyl, aryl or heteroaryl group substituted by a alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with at least one substituent selected from the group consisting of a halogen and a pendant basic nitrogen functionality; or

a -SO₂-R'' group wherein R'' is an alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with at least one substituent selected from the group consisting of a halogen and a pendant basic nitrogen functionality; or a -CO-R' or a -CO-NR'R'' group, wherein R' and R'' are independently chosen from H or an aryl heteroaryl, alkyl and cycloalkyl group optionally substituted with at least one substituent selected from the group consisting of a halogen and a pendant basic nitrogen functionality.

95. (New) A compound according to claim 94 selected from the group consisting of

4-Hydroxy-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide(example 037);

Thiophene-2-sulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester (example 042);

4-Iodo-benzenesulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester (example 043);

4-Isopropoxy-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 050);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(2-morpholin-4-yl-ethoxy)-benzamide (example 052);

3-Fluoro-benzenesulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester (example 056);

2-Fluoro-benzenesulfonic acid 4-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-phenyl ester (example 058); and

3-Methoxy-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 059);

96. (new) A compound according to claim 63 selected from the group consisting of

4-[3-(4-Bromo-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide(example 036);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-(3-thiophen-2-yl-ureido)-benzamide (example 038);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-(thiophene-2-sulfonylamino)-benzamide (example 044);

4-[3-(2-Iodo-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 101); and

4-[3-(4-Fluoro-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 102);

97. (New) A compound selected from the group consisting of

1-(4-Methoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 009);

1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea (example 011);

1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-(3,4,5-trimethoxy-phenyl)-urea (example 013);

4-{3-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-ureido}-benzoic acid ethyl ester (example 014);

1-Cyclohexyl-1-(N-Cyclohexyl-formamide)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 016);

1-(2,4-Dimethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 017);

1-(2-Iodo-phenyl)-1-(N-(2-Iodo-phenyl)-formamide)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 018);

1-(4-Difluoromethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-urea (example 021);

1-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-p-tolyl-urea (example 026);

(4-Hydroxymethyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 030);

4-(3-{4-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]carbamoyl}-phenyl)-ureido)-benzoic acid ethyl ester (example 034);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-[3-(4-trifluoromethyl-phenyl)-ureido]-benzamide (example 035);

4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 039);

4-[3-(4-Methoxy-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 040);

4-[3-(4-Difluoromethoxy-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 041);

2-Fluoro-5-methyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 048);

4-tert-Butyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 049);

Benzo[1,3]dioxole-5-carboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide (example 051);

3-Cyano-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 054);

2-Fluoro-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide (example 055);

3-Methyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 0061);

Biphenyl-3-carboxylic acid [4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-amide (example 062);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide (example 065);

{4-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenylcarbamoyl]-benzyl}-carbamic acid tert-butyl ester(example 073);

3-Fluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 074);

4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide (example 075);

4-(1-Methoxy-ethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 083);

N-[4-Methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-4-[3-(4-trifluoromethyl-phenyl)-ureidomethyl]-benzamide (example 086);

4-Cyano-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 103);

4-[3-(2,4-Dimethoxy-phenyl)-ureido]-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 100); and

3-Bromo-4-methyl-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide (example 105).